Scholarly Index
Teresa Macarulla
Vall d'Hebron Hospital Universitari; 21,173 total citations; 518 total publications; best world rank #14
Vall d'Hebron Hospital Universitari
21,173Total citations
518Total publications
62H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Pancreatic and Hepatic Oncology Research | Lifetime | 355 | ES 3 | 99.04 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 320 | ES 4 | 98.59 |
| Colorectal Cancer Treatments and Studies | Lifetime | 555 | ES 18 | 98.39 |
| Cancer Treatment and Pharmacology | Lifetime | 897 | ES 26 | 97.64 |
| Fibroblast Growth Factor Research | Lifetime | 695 | ES 6 | 92.15 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 14 | ES 1 | 99.69 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 19 | ES 1 | 99.51 |
| Cancer Genomics and Diagnostics | 2021-2025 | 140 | ES 6 | 98.92 |
| Fibroblast Growth Factor Research | 2021-2025 | 23 | ES 1 | 95.50 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 170 | ES 6 | 95.95 |
| Peptidase Inhibition and Analysis | 2021-2025 | 225 | ES 15 | 95.15 |
| Gallbladder and Bile Duct Disorders | 2021-2025 | 328 | ES 8 | 94.54 |
| Renal cell carcinoma treatment | 2021-2025 | 507 | ES 9 | 92.88 |
| Cancer Mechanisms and Therapy | 2021-2025 | 288 | ES 8 | 86.24 |
| PARP inhibition in cancer therapy | 2021-2025 | 634 | ES 22 | 83.94 |
| Cancer Research and Treatments | 2021-2025 | 741 | ES 8 | 81.04 |